Alnylam shares reach historic high after breakthrough for RNAi therapeutics

Massachusetts, USA-based Alnylam Pharmaceuticals (Nasdaq: ALNY) is presenting detailed data from its Phase III APOLLO study into patisiran at the European ATTR Amyloidosis Meeting in Paris.

The company’s share price, which was already riding high after topline results, revealed in September, showed the candidate had met its primary and secondary endpoints, is already up more than 15% on the news.

Patisiran is an experimental therapy that targets the hereditary form of ATTR amyloidosis, a rare and severe disease in which abnormal proteins accrete in the body.